RT Journal Article
T1 The SADDEN DEATH Study: Results from a Pilot Study in Non-ICU COVID-19 Spanish Patients
A1 Pérez García, Carlos Nicolás
A1 Enríquez Vázquez, Daniel
A1 Méndez Bailón, Manuel
A1 Olmos, Carmen
A1 Gómez Polo, Juan Carlos
A1 Iguarán Bermúdez, Rosario
A1 Ramos López, Noemí
A1 García Klepzig, José Luis
A1 Ferrández Escarabajal, Marcos
A1 Jerónimo, Adrián
A1 Martínez Gómez, Eduardo
A1 Font Urgelles, Judit
A1 Fragiel Saavedra, Marcos
A1 Paz Arias, Pilar
A1 Romero Delgado, Teresa
A1 Gómez Álvarez, Zaira
A1 Playán Escribano, Julia
A1 Jaén, Esther
A1 Vargas, Gianna
A1 González, Elizabeth
A1 Orviz, Eva
A1 Burruezo, Irene
A1 Calvo, Alberto
A1 Nieto Sánchez, Ángel
A1 Molino González, Ángel Manuel
A1 Lorenzo Villalba, Noel
A1 Andrès, Emmanuel
A1 Macaya, Carlos
A1 Vila Costa, Isidro
AB Introduction: The worldwide pandemic, coronavirus disease 2019 (COVID-19) is a novel infection with serious clinical manifestations, including death. Our aim is to describe the first non-ICU Spanish deceased series with COVID-19, comparing specifically between unexpected and expected deaths. Methods: In this single-centre study, all deceased inpatients with laboratory-confirmed COVID-19 who had died from March 4 to April 16, 2020 were consecutively included. Demographic, clinical, treatment, and laboratory data, were analyzed and compared between groups. Factors associated with unexpected death were identified by multivariable logistic regression methods. Results: In total, 324 deceased patients were included. Median age was 82 years (IQR 76–87); 55.9% males. The most common cardiovascular risk factors were hypertension (78.4%), hyperlipidemia (57.7%), and diabetes (34.3%). Other common comorbidities were chronic kidney disease (40.1%), chronic pulmonary disease (30.3%), active cancer (13%), and immunosuppression (13%). The Confusion, BUN, Respiratory Rate, Systolic BP and age ≥65 (CURB-65) score at admission was >2 in 40.7% of patients. During hospitalization, 77.8% of patients received antivirals, 43.3% systemic corticosteroids, and 22.2% full anticoagulation. The rate of bacterial co-infection was 5.5%, and 105 (32.4%) patients had an increased level of troponin I. The median time from initiation of therapy to death was 5 days (IQR 3.0–8.0). In 45 patients (13.9%), the death was exclusively attributed to COVID-19, and in 254 patients (78.4%), both COVID-19 and the clinical status before admission contributed to death. Progressive respiratory failure was the most frequent cause of death (92.0%). Twenty-five patients (7.7%) had an unexpected death. Factors independently associated with unexpected death were male sex, chronic kidney disease, insulin-treated diabetes, and functional independence. Conclusions: This case series provides in-depth characterization of hospitalized non-ICU COVID-19 patients who died in Madrid. Male sex, insulin-treated diabetes, chronic kidney disease, and independency for activities of daily living are predictors of unexpected death.
PB MDPI
SN 2077-0383
YR 2021
FD 2021
LK https://hdl.handle.net/20.500.14352/7365
UL https://hdl.handle.net/20.500.14352/7365
LA eng
DS Docta Complutense
RD 9 abr 2025